MENLO PARK, Calif., Jan. 11 /PRNewswire/ -- ForteBio(R), Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Dip and Read Residual Protein A Detection Kit for use on the company's Octet platform. The new assay enables drug developers to accurately identify and measure levels of Protein A with unprecedented speed and minimal hands-on time. The company also announced the introduction of its Sidekick Offline Biosensor Immobilization Station, which enables offline loading of reagents on biosensors, in tandem with any Octet instrument, for enhanced efficiency and assay performance.
"Protein A detection is a critical quality control step during drug development and manufacturing, but traditional methods are labor-intensive, complicated and time-consuming," said Christopher Silva, ForteBio's vice president of marketing. "Our new Dip and Read Residual Protein A Detection Kit offers the same sensitivity levels as existing methods, but requires significantly less hands-on time and can be completed in half the time."
"Our Sidekick instrument enables more samples to be run in significantly less time and with greater assay performance. It is ideal for rapid custom biosensor batch preparation and multistep Octet sandwich assays, which are used to detect impurities - such as residual Protein A in therapeutic antibody products," said Mr. Silva.
About ForteBio, Inc.
ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.
CONTACT: Gemma Milan of ForteBio, +1-650-289-6800, gmilan@fortebio.com
Web site: http://www.fortebio.com/
